Navigation Links
NKTR-102 Demonstrates Significant Efficacy as Single-Agent in Second- or Third-Line Treatment in Metastatic Breast Cancer Patients
Date:12/12/2010

at the Institut Jules Bordet in Brussels, Belgium.  "The high confirmed objective response rate continues to show that NKTR-102 is one of the most active single agents in this disease.  This is particularly evident given the number of patients with dramatic reduction in lung and liver metastases."

The confirmed ORR was maintained in poor prognosis and heavily pre-treated subsets within the study, including patients previously treated with anthracycline/taxane/capecitabine: 33% (5/15); patients with metastatic triple-negative breast cancer: 39% (7/18); and patients with visceral disease: 29% (17/58).  As of October 26, 2010, preliminary median progression-free survival (PFS) for all patients was 20 weeks. [Efficacy Tables, Figures A - C]

"We are in critical need of effective new therapeutic options whose mechanism of action is different from those already available for women with metastatic breast cancer," continued Dr. Awada.  "This is especially true for those patients whose disease has progressed despite treatment with anthracyclines and taxanes.  NKTR-102 is emerging as an important investigational treatment in metastatic breast cancer and has the potential to be the first topoisomerase 1 inhibitor in this disease.  NKTR-102 should enter Phase 3 clinical studies as quickly as possible."

Patients treated in the single-agent NKTR-102 study had a median of two lines of prior cytotoxic treatments for metastatic disease.  Seventy-three percent (51/70) of the patients received neoadjuvant and/or adjuvant therapy and 87% (61/70) had visceral disease.  

"NKTR-102 is quickly emerging as a very important potential new drug in the fight against cancer," said Lorianne Masuoka, M.D., Senior Vice President and Chief Medical Officer.  "The drug has consistently high response rates as a single-agent in multiple Phase 1 and 2 clinical studies to-date, including our study in platinum-resistant ova
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress
2. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
3. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
4. Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings
5. Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting
6. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
7. NKTR-102 (PEG-Irinotecan) Demonstrates Significant Tumor Growth Inhibition In Multiple Preclinical Tumor Models
8. Tumor Growth Inhibition and Pharmacokinetic Profile of NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors To Be Presented at Upcoming AACR-NCI-EORTC International Conference
9. Phase 2 Data Presented at the 52nd Annual Meeting of the American Society of Hematology Demonstrates Promising Efficacy of KRX-0401 (Perifosine) in the Treatment of Advanced Leukemia, Lymphoma and Multiple Myeloma
10. Halozymes rHuPH20 With Recombinant Human Insulin Demonstrates Glycemic Control Comparable to Lispro
11. Pevions Breakthrough Candida Vaccine Demonstrates Safety and Immunogenicity in Phase I Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... 27, 2015 Bronstein, Gewirtz & Grossman, LLC ... the securities of Celladon Corporation ("Celladon" or the "Company") ... Peretz Bronstein or his investor relations coordinator ... 212-697-6484. The investigation concerns whether Celladon and ... 10(b) and 20(a) of the Securities Exchange Act of ...
(Date:4/27/2015)... 27, 2015 Vermillion, Inc. (VRML), ... disease, announced today it will report first ... close on Monday, May 11, 2015, followed ... at 4:30pm Eastern.Conference Call & Webcast: Monday, ... Domestic: , 888-556-4997International: , 719-457-2628Conference ID: , ...
(Date:4/27/2015)... , April 27, 2015  Novira Therapeutics, Inc., a ... curative treatment of chronic hepatitis B virus (HBV) infection, ... its lead HBV core inhibitor candidate, NVR 3-778, at ... the Study of the Liver (EASL) in ... of NVR 3-778 from studies performed in a humanized ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Celladon Corporation 2Novira Therapeutics Announces Presentation of Preclinical Antiviral Data for NVR 3-778 at EASL 2Novira Therapeutics Announces Presentation of Preclinical Antiviral Data for NVR 3-778 at EASL 3
... 2011 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: ... and commercialization of products for central nervous system disorders, ... one of Israel,s leading private biotech, pharmaceutical and medical ... Israel. "We are excited to reach this ...
... Cell Therapeutics, Inc. ("CTI") (NASDAQ: CTIC ... that final results from the phase II OPAL study ... acute myeloid leukemia (AML) were presented by Jorge Cortes, ... Center during the Acute Myeloid Leukemia - Therapy, excluding ...
Cached Medicine Technology:Vanda Pharmaceuticals Enters into an Exclusive License Agreement with Megapharm Ltd. for Commercialization of Fanapt™ in Israel 2Vanda Pharmaceuticals Enters into an Exclusive License Agreement with Megapharm Ltd. for Commercialization of Fanapt™ in Israel 3Vanda Pharmaceuticals Enters into an Exclusive License Agreement with Megapharm Ltd. for Commercialization of Fanapt™ in Israel 4Final OPAL Phase II Results of Tosedostat Demonstrate Significant Response Rates in Elderly Patients with Treatment Refractory or Relapsed Primary or Secondary Acute Myeloid Leukemia (AML) 2Final OPAL Phase II Results of Tosedostat Demonstrate Significant Response Rates in Elderly Patients with Treatment Refractory or Relapsed Primary or Secondary Acute Myeloid Leukemia (AML) 3Final OPAL Phase II Results of Tosedostat Demonstrate Significant Response Rates in Elderly Patients with Treatment Refractory or Relapsed Primary or Secondary Acute Myeloid Leukemia (AML) 4
(Date:4/27/2015)... According to a recent report from ... chronic back pain, TMJ disorders are the second ... disability. In addition, the report revealed that TMJ disorders ... costing an estimated 4 billion dollars annually. , These ... seemingly unrelated symptoms such as headaches, neck pain, tenderness ...
(Date:4/27/2015)... Thanks to a $7.5 million grant from ... institutions, including American University, will operate in a new ... behavioral research aimed at ending the AIDS epidemic. , ... HIV or AIDS, according to the latest statistics. At ... over the age of 13 was living with HIV, ...
(Date:4/27/2015)... April 27, 2015 Doctors on Liens ... on a lien basis for over twenty years. So when ... the best doctor in the Fresno area , Doctors ... DC and his team of medical specialists. With a ... massage therapist, Dilanchian Chiropractic is now helping more ...
(Date:4/27/2015)... Church, VA (PRWEB) April 27, 2015 ... Integrity Issues Within Your Operations or Your Partners/Suppliers, **FDAnews ... p.m. EDT, http://www.fdanews.com/DataIntegrity , Data integrity issues ... the last few years., Uncovering data integrity issues within ... once data integrity issues come to light, remediating them ...
(Date:4/27/2015)... (PRWEB) April 27, 2015 FMC Corporation’s ... exhibit its wide range of market leading ingredients and ... 7 in Geneva, Switzerland. Vitafoods Europe 2015 expects to ... countries showcasing the latest research in such areas as ... , FMC Health and Nutrition’s booth will feature ...
Breaking Medicine News(10 mins):Health News:Dentist in Graham NC Reveals that a Jaw Disorder May Be the Cause of Chronic Headaches and Back Pain 2Health News:D.C. Center for AIDS Research Established with New Grant from NIH 2Health News:D.C. Center for AIDS Research Established with New Grant from NIH 3Health News:Eminent Doctor Joins Forces with Doctors on Liens in Fresno 2Health News:FDAnews Announces — Data Integrity Problems on the Rise: Confronting Data Integrity Issues Within Your Operations or Your Partners/Suppliers Webinar, May 19, 2015 2Health News:FDAnews Announces — Data Integrity Problems on the Rise: Confronting Data Integrity Issues Within Your Operations or Your Partners/Suppliers Webinar, May 19, 2015 3Health News:FDAnews Announces — Data Integrity Problems on the Rise: Confronting Data Integrity Issues Within Your Operations or Your Partners/Suppliers Webinar, May 19, 2015 4Health News:FMC Health and Nutrition to Feature Epax® Brand Omega-3 Ingredients at Vitafoods Europe 2015 2
... ... some people have questioned if the HCG diet can be harmful. Dr Robert True addresses ... , ... Dr. Robert sees patients on a daily basis that he helps lose weight through his ...
... ... BtoB companies seeking a proven approach for lead cultivation with social media. , ... Portland, OR (PRWEB) March 24, 2010 -- ... Five Ways to Leads: How BtoBs Should Use Social Media , a complimentary Webinar event ...
... This release is available in Spanish . ... same area as the original tumour remains the strongest, independent ... who have been free of disease for a very long ... European Breast Cancer Conference (EBCC7). Dr Sven Mieog, MD, ...
... available in Spanish . Barcelona, Spain: ... goal in survival with new treatment should be to prolong ... might expect from using current best therapies, a researcher will ... today (Wednesday). This finding contrasts with doctors, perception that an ...
... the Barcelona Public Health Agency has revealed those sections of ... published in the journal Respiratory Research , shows that ... aged over 50 or infected with HIV. "Some patients ... of six months), resulting in a danger of them infecting ...
... the death of a loved one can provide much-needed consolation ... study in the April issue of the Journal of ... a relative to cancer took part in the study. Participants ... widows, widowers, daughters and sisters. Nine chose foot massage, eight ...
Cached Medicine News:Health News:HCG True Diet – Dr. Robert True Speaks About the Importance of Medical Supervision for HCG Diets 2Health News:Webinar Shares Proven Social Media Approach to BtoB Lead Generation 2Health News:Recurrence of breast cancer after more than 10 years is an important indicator of survival 2Health News:Recurrence of breast cancer after more than 10 years is an important indicator of survival 3Health News:What should be the goal of treatment in metastatic breast cancer? 2Health News:What should be the goal of treatment in metastatic breast cancer? 3Health News:Older people and those with HIV are more vulnerable to tuberculosis 2Health News:Hand and feet massages provide consolation for bereaved relatives 2
... patented ratchet design provides fingertip ratchet disengagement ... I Instrument program offers state-of-the-art quality in ... maintaining strength and durability. Low profile cutting ... joint spaces. Series I instruments are available ...
... ratchet design provides fingertip ratchet disengagement allowing ... Instrument program offers state-of-the-art quality in an ... strength and durability. Low profile cutting tips ... spaces. Series I instruments are available in ...
... patented ratchet design provides fingertip ratchet disengagement ... I Instrument program offers state-of-the-art quality in ... maintaining strength and durability. Low profile cutting ... joint spaces. Series I instruments are available ...
... A broad selection of procedurally specific ... and allow easy access to all ... variety of approaches.,Loop Handled Graspers feature ... holds tissue firmly without tearing or ...
Medicine Products: